BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20708999)

  • 1. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
    Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
    Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
    Chaitra MG; Nayak R; Shaila MS
    Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
    Meraldi V; Romero JF; Kensil C; Corradin G
    Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
    Otero M; Calarota SA; Felber B; Laddy D; Pavlakis G; Boyer JD; Weiner DB
    Vaccine; 2004 Apr; 22(13-14):1782-90. PubMed ID: 15068862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
    Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
    Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
    Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
    Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.